EUCTR2010-020394-17-DE进行中（未招募）不适用
A Phase 1-2 trial of MM-121 in Combination with Erlotinib in Three Groups of Patients with Non-Small Cell Lung Cancer
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 229
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patients with locally advanced or metastatic non-small cell lung cancer.
- •- Patients must be >/= 18 years of age.
- •- Patients must have adequate Performance Status (PS) as measured by ECOG and adequate end organ function.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 154
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 75
排除标准
- •- Patients with a recent history (within 5 years) of another malignancy.
- •- Patients who are pregnant or nursing.
- •- Patients with clinically significant heart failure.
- •- Patients with clinically significant eye or gastrointestinal abnormalities.
研究者
相似试验
进行中（未招募）
不适用
A trial to determine wether adding a new drug to an existing treatment is safe and helps people with lung cancerEUCTR2010-020394-17-ESMERRIMACK PHARMACEUTICALS229
已完成
1 期
A Study of MM-121 Combination Therapy in Patients With Advanced Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungNCT00994123Merrimack Pharmaceuticals162
进行中（未招募）
1 期
A Phase 2 Study of MM-121 in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Heregulin Positive Non-Small Cell Lung Cancer.Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 18.1Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003673-42-ESMerrimack Pharmaceuticals, Inc.120
已完成
1 期
A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast CancersLocally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,Primary Peritoneal Cancer or Endometrial CancerLocally Advanced/Metastatic Her2 Non Overexpressing Breast CancerNCT01209195Merrimack Pharmaceuticals41
进行中（未招募）
1 期
SHERLOC: A Phase 2 Study of MM-121 in Combination with Chemotherapy versus Chemotherapy Alone in Patients with Heregulin Positive Non-Small Cell Lung Cancer.Heregulin Positive, Locally Advanced or Metastatic Non-Small Cell Lung CancerMedDRA version: 20.0Level: PTClassification code 10059515Term: Non-small cell lung cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2014-003673-42-DEMerrimack Pharmaceuticals, Inc.135